Introduction {#s1}
============

Antimicrobial resistance is growing and is now recognized as a major global health threat ([@B34]). It is responsible for an estimated 700,000 deaths a year (25,000 in the European Union) and is associated with annual expenditure and productivity losses amounting to €1.5 billion ([@B8]). If the current trend is not reversed, estimates indicate that by 2050 antimicrobial resistance could result in 10 million deaths each year and economic losses of up to \$100 trillion dollars ([@B19]).

Spain is one of the highest consumers of antibiotics in the developed world. Total antibiotic consumption in 2016 was 32.9 defined daily doses per 1,000 inhabitants per (DID) ([@B7]). compared with 22.8 DID for the European Union and 10.4 for the Netherlands. In the public PHC setting, consumption increased significantly from 19.70 DID in 2012 to 23.00 DID in 2016 ([@B5]) (overall increase of 12.69%).

Outpatient antibiotic use has been clearly correlated with antibiotic resistance in specific geographic areas, and it may even influence resistance rates in hospital settings ([@B23]; [@B10]). Between 2001 and 2016, *Escherichia coli* resistance to third-generation cephalosporins increased from 0.6 to 15.0% in Spain and from 0.6 to 6.4% in the Netherlands ([@B27]; [@B6]).

The 2016 Centers for Disease Control and Prevention (CDC) publication on outpatient antibiotic stewardship describes four core elements for assessing and improving antibiotic prescribing in outpatient settings: 1) commitment, 2) action for policy and practice, 3) tracking and reporting, 4) and education and expertise ([@B22]). In 2014, the Spanish Ministry of Health published a 5-year national strategic plan for combating antimicrobial resistance ([@B26]). The main objective was to reduce the risk of selection and spread of antibiotic resistance, but the document also highlighted the importance of promoting actions to improve antibiotic prescribing ([@B26]). In line with this strategic plan and with the recommendations of the CDC ([@B26]), we implemented a multifaceted, real-world, antimicrobial stewardship program (ASP) aimed at reducing overall and specific use of antibiotics in a primary health care (PHC) area in Spain. No previous interventions had been conducted in this area.

Material and Methods {#s2}
====================

Design and Setting {#s2_1}
------------------

We performed a quasi-experimental study to evaluate the program. Data were collected in three phases: a baseline phase (January--December 2016), an intervention phase (January--December 2017), and a sustainability phase (January--December 2018).

The setting for the intervention was a PHC area in the province of Barcelona that serves a population of 260,657 inhabitants and has nine PHC centers, a 400-bed acute care teaching hospital managed by the same health organization, together with 18 nursing homes. The Spanish national health care system offers universal coverage to a population of 46.4 million inhabitants (2016) ([@B2]). The country has 17 autonomous communities, each of which is responsible for offering regional health care services with oversight from the Spanish Ministry of Health. The country has approximately 13,000 PHC centers and 457 hospitals, and each regional health authority collects data on all prescriptions issued within the public health care system ([@B2]).

Participants {#s2_2}
------------

The ASP targeted 130 PHC physicians, 41 PHC pediatricians, 19 emergency physicians, and 18 nursing home physicians. It also included an educational campaign targeting patients. All physicians and patients were included, no sampling was made.

Intervention {#s2_3}
------------

All components of the ASP were implemented simultaneously by the PHC antimicrobial stewardship team set up in 2016 to work in coordination with the hospital-based team formed 3 years earlier. The PHC team is composed of 10 PHC physicians, four PHC pediatricians, three clinical pharmacists, an infectious disease specialist, and a microbiologist.

The components of the intervention, all evidence-based and detailed below, were selected to align with the CDC's four core elements of outpatient antibiotic stewardship ([@B22]).

a.  *Commitment to the ASP*. Thirty minute face-to-face sessions were organized to present the ASP to all relevant stakeholders in the PHC area (management, center directors, general physicians, pediatricians, and emergency physicians). Twenty-five sessions were held to ensure 100% coverage and 150 poster reminders were distributed among the physicians' offices and the emergency areas of the participating PHC centers. In case that a new physician was hired during the intervention or sustainability phase the AS Team presented the project and provided the educational material through a face-to-face meeting. A member of the antimicrobial stewardship team visited each of the nursing homes to explain the intervention to the physicians working there and provide them with educational material on good antibiotic prescribing practices. All care providers were asked to commit to the ASP but were not required to sign any documents to this effect. No financial incentives were offered.

b.  *Actions for improving antibiotic prescribing*. All PHC centers were supplied with a rapid test for detecting *Streptococcus pyogenes* and an accompanying protocol based on the Centor clinical scoring scale (modified McIsaac score) to ensure correct use of the test ([@B9]).

c.  *Tracking and feedback*. Every 3 months, physicians received an updated anonymized report containing qualitative and quantitative indicators on antibiotic consumption in their PHC center (see [**Supplementary data**](#SM1){ref-type="supplementary-material"} for sample report). The report contained a comparison with the same period from the previous year and also allowed physicians to compare their performance with that of other physicians and with the center overall. The data were presented as part of an interactive clinical workshop.

d.  *Education and experience*. The antimicrobial stewardship team also prepared a set of local guidelines on antibiotic usage and preferred regimens for adult and pediatric patients. These guidelines were distributed to physicians and were also accessible through the centralized health organization website. A total of 500 printed guidelines were distributed. In addition, 60 interactive workshops of 45 min duration were held in all the participating centers to discuss clinical cases involving respiratory tract, urinary tract, and skin and soft tissue infections. The average participant rate in the face-to-face session was 66% (125 physicians) and 85% participated in at least one session. All physicians received the workshop material by email. Over 600 project-related emails were sent. Finally, purpose-designed educational leaflets and posters (n = 150) on safe antibiotic use targeting patients were placed in waiting rooms and common areas.

Outcomes {#s2_4}
--------

Antibiotic consumption was measured in DID day calculated with drug packages in all cases. The primary outcome was overall antibiotic consumption. Secondary outcomes were i) consumption of amoxicillin (ATC: J01CA04), amoxicillin/clavulanic acid (ATC: J01CR02), macrolides (ATC: J01FA, including: J01FA02 spiramycin, J01FA07 josamycin, J01FA09 clarithromycin and J01FA10 azithromycin), and quinolones (ATC: J01M, including: J01MA02 ciprofloxacin, J01MA06 norfloxacin, J01MA12 levofloxacin and J01MA14 moxifloxacin) (the main antibiotics prescribed in PHC); ii) consumption of narrow-spectrum antibiotics (penicillins with extended spectrum \[ATC: J01CA, including: J01CA01 ampicillin and J01CA04 amoxicillin\], beta-lactamase sensitive penicillins \[ATC: J01CE, including: J01CE01 benzylpenicillin, J01CE02 phenoxymethylpenicillin, J01CE08 benzathine benzyl penicillin, J01CE10 benzathine phenoxymethylpenicillin, J01CE30 combinations\], beta-lactamase resistant penicillins \[ATC: J01CF, including: J01CF02 cloxacillin\], and fosfomycin \[J01XX01\]); Antibiotics with less than 0.00 DID was considered negligible. iii) percentage of patients treated with antibiotics for common PHC conditions (pharyngotonsillitis, acute otitis media, acute sinusitis, acute bronchitis, and urinary tract infections); iv) direct costs associated with antibiotic consumption; v) unique patients prescribed at least one course of antibiotics; and vi) antibiotic consumption in nursing homes measured as defined daily doses per 100 bed days (DDBs). Indicators were measured at baseline and during the intervention and sustainability phases.

Data Collection {#s2_5}
---------------

Data were extracted from the patients' electronic medical records throughout the study period. Patient contacts were traced by checking records for ICD-9 codes for relevant infections and ATC codes for antibiotic prescriptions. In order to calculate the economic indicator, the reference prices for drugs stablished by the Ministry of Health, Consumer Affairs and Social Welfare of Spain were applied ([@B21]).

Statistical Analysis {#s2_6}
--------------------

A descriptive analysis was performed for each outcome indicator using data collected before and after the intervention (baseline/2016 *vs.* sustainability phase/2018). Proportions and SDs were used for the descriptive statistics. Proportions of categorical variables in two or more independent groups were compared using the Chi-square test. P-values ≤ 0.05 were considered statistically significant. When required, statistical trend analyses were carried out to evaluate the significance of temporal variations. All endpoint definitions and statistical methods were predefined in a statistical analysis plan before evaluation of the data. Analyses were performed using Stata 13 (Stata Corporation, College Station, TX, USA).

The project was approved by the Mútua Terrassa Research Ethics Committee; informed consent was not required according to institutional and national guidelines.

Results {#s3}
=======

Demographic Characteristics {#s3_1}
---------------------------

Data were analyzed for 260,561 patients, 50.89% of whom were female. The mean (SD) age was 40.85 (22.81) years; 20.98% of the patients were pediatric (0--14 years old) and 16.07% were aged 65 years or older. The study population included 1,964 nursing home residents with a mean age of 79.99 (8.22) years. A mean of 181,863 unique-patient visits per year was registered over the study period.

Quantitative Indicators {#s3_2}
-----------------------

Overall antibiotic consumption decreased by 16.85% (16.01 to 13.31 DID) between 2016 (baseline) and 2018 (sustainability period). It decreased by 16.94% in the adult population (17.34 to 14.41 DID) and by 19.22% in the pediatric population (10.05 to 8.12 DID). The percentage of patients treated with antibiotics also decreased, from 26.99% in 2016 to 22.41% in 2018 (−4.57%; p \< 0.05). Overall antibiotic consumption decreased in both adults and children but the largest decrease (26.00%) was observed in nursing home residents (7.74 DDB in 2016 to 5.72 DDB in 2018).

On analyzing consumption of specific antibiotics, significant reductions were observed for amoxicillin (4.75 to 4.08 DID; −14.12%), amoxicillin/clavulanic acid (6.04 to 4.72 DID; −21.88%), quinolones (1.64 to 1.23 DID; −25.06%), and macrolides (1.73 to 1.43 DID; −17.18%). Consumption of narrow-spectrum antibiotics increased from 31.32 to 32.35% (+1.04%; p \< 0.05). The overall results of the ASP are summarized in [**Tables 1** and **2**](#SM1){ref-type="supplementary-material"}.

Qualitative Indicators {#s3_3}
----------------------

The percentage of adults diagnosed with pharyngotonsillitis and treated with antibiotics decreased significantly from 64.81% in 2016 to 54.38% in 2018 (−10.43%; p \< 0.05). The corresponding reduction for children was 12.68% (56.53 to 43.85%, p \< 0.05). In both adult and pediatric patients, there was a significant increase in the use of amoxicillin to treat pharyngotonsillitis and a decrease in the use of amoxicillin/clavulanic acid and macrolides. Further information over qualitative data for the treatment of pharyngotonsillitis in the three periods of study is shown in [**Table 3**](#SM1){ref-type="supplementary-material"}.

The proportion of patients with acute otitis media treated with antibiotics also decreased: from 58.26 to 49.53% (−8.72%; p \< 0.05) in the case of adults and from 72.37 to 68.09% (−4.28%, p \< 0.05) in the case of children. As with pharyngotonsillitis, there was a significant increase in the use of amoxicillin and a decrease in that of amoxicillin/clavulanic acid and macrolides in the adult and pediatric populations. Further information over qualitative data for the treatment of acute otitis media in the three periods of study is shown in [**Table 4**](#SM1){ref-type="supplementary-material"}.

Nonsignificant changes were observed for the percentage of patients with urinary tract infections treated with antibiotics. Adults increased from 70.94 to 71.40% (0.46%; p = 0.69), and children decreased from 51.15 to 49.28% (−1.87%; p = 0.51). In adults, the use of fosfomycin and cefuroxime increased from 39.58 to 45.36% and 26.76 to 29.93% while that of amoxicillin/clavulanic acid and quinolones decreased from 6.15 to 4.24% and 27.52 to 20.47%, respectively. Further information over qualitative data for the treatment of UTI in the three periods of study is shown in [**Table 2**](#SM1){ref-type="supplementary-material"} of the [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.

Finally, there was a significant decrease in the use of antibiotics to treat acute bronchitis in both adults (70.06 to 58.65%; −11.42%; p \< 0.05) and children (29.19 to 22.78%; −2.14%; p \< 0.05). In the case of acute sinusitis, antibiotic use fell significantly in adults (77.50 to 68.12%; −9.38%; p \< 0.05) but increased, albeit insignificantly, in children (from 80.64 to 81.27%; 0.64%; p = 0.50). Further information over the percentage of patients treated with antibiotic with diagnosis of acute sinusitis and acute bronchitis is shown in [**Table 3**](#SM1){ref-type="supplementary-material"} of the [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.

Economic Indicators {#s3_4}
-------------------

Total spending on antibiotics fell from €905,700.76 during the baseline phase to €793,765.89 during the sustainability phase (overall saving of €111,934.87), reductions were observed in the total spending of Amoxicillin/Clavulanic (overall saving of €45,935.76) and Quinolones (overall saving of €43,475.17) in correlation with the decrease in DID. Economic data for the baseline, intervention, and sustainability phases are shown in [**Table 4**](#SM1){ref-type="supplementary-material"} of the [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.

Discussion {#s4}
==========

The findings of this quasi-experimental study show that a multifaceted ASP reduced overall antibiotic consumption and costs in a PHC area. Our study supports previous reports that behavioral and educational interventions lead by pharmacists can improve antibiotic prescribing practices ([@B11]; [@B12]; [@B17]). In 2017 Mohsen Ali Murshid et al. developed a theoretical model of prescribing decision based on the review of previous theoretical models. The authors suggested the possible relationship between various variables related to physician decision prescribing such as pharmacy--physician collaboration or patient's expectations ([@B18]).

The primary aim of our intervention was to reduce antibiotic consumption and we achieved an absolute reduction of 16.85% between 2016 and 2018. The corresponding reduction in antibiotic prescriptions in the Spanish national health care system was 4.99% ([@B7]), which is slightly lower than the rate of 6.53% reported for Sweden, which has one of the lowest antibiotic consumption rates in Europe ([@B17]).

Use of narrow-spectrum antibiotics in our PHC area increased by 1.04%, which is just slightly higher than the increase of 0.44% reported for the Spanish public health care system for the same period ([@B7]). Use of amoxicillin/clavulanic acid in our area fell to 4.08 DID in 2018. This compares with 7.57 DID for Spain as a whole and 0.31 for Sweden. The respective figures for quinolones were 1.23 DID for our PHC area, 2.71 DID for Spain, and 0.60 DID for Sweden. Overall, 22.69% of our population was treated with at least one course of antibiotics compared with 17.4% of the Swedish population ([@B29]). It should be recalled that our figures do not include prescriptions issued in private practice. Differences in antibiotic consumption between both countries are multifactorial, but we believe one of the key elements is that Sweden has been working in a National Strategic Program against antibiotic resistance (known as Strama) ([@B28]) since 1995 with multifaceted interventions and multiprofessional teams on both national and local levels. In Spain the first National Strategic Program against antibiotic resistance was published in 2014, 19 years later. The larger reduction achieved in our PHC area can probably be explained by the fact that local strategies tend to have a greater impact than national ones, national strategies should promote and coordinate local ASP.

Most antimicrobial stewardship interventions to date have targeted single conditions ([@B20]; [@B32]). In a systematic review of interventions to reduce unnecessary antibiotic prescribing, 38 of the 43 studies analyzed addressed acute respiratory infections only ([@B20]). We decided to adopt a more comprehensive approach, as antibiotic consumption in our PHC area had increased by 13.78% between 2012 (14.00 DID) and 2016 (16.01 DID). We targeted pharyngotonsillitis, acute otitis media, acute sinusitis, acute bronchitis, and urinary tract infections as these are the most common diagnoses for which antibiotics are prescribed in our setting and they have also been associated with overprescribing ([@B15]; [@B16]; [@B12]; [@B33]; [@B30]; [@B24]; [@B13]).

Overall, 68.12% of patients with acute sinusitis were treated with antibiotics during the sustainability phase of our study. This is slightly higher than the rate of 60.6% reported for Sweden in 2013 ([@B30]) and considerably lower than that of 80% reported for the United States ([@B13]). The corresponding rate for acute otitis media infections treated with antibiotics in our area was 49.53%, which contrasts with the respective rates of 45.8 and 74.9% reported for the Netherlands ([@B31]) and Sweden ([@B30]). Urinary tract infections were treated with antibiotics in 71.40% of the patients in our study *versus* 60.4% of those in the Netherlands ([@B31]). The antibiotic prescribing rate for sore throat (including pharyngitis and tonsillitis) in our study is similar to rates reported for the United Kingdom (62%) ([@B14]), the United States (60%) ([@B1]), and Sweden (60%) ([@B30]). In this case, only the Netherlands had a lower rate (55%) ([@B14]). Our findings for acute bronchitis suggest there is much room for improvement in this area, as 58.65% of patients presenting with this condition were prescribed antibiotics *versus* just 26.2% of those in Sweden ([@B30]) and 52.1% of those in the Netherlands ([@B31]). Differences in prescription rates could be due to structural or organizational differences, such as nurse triage processes or PHC physicians recording practices. In Sweden nurses' triage is performed according to guidelines which in many cases avoid the need for patients to visit PHC physicians ([@B30]). As for electronic medical records (EMR), not all health care organizations use the same classification of diseases. We used ICD codes, but the existence of other options such as the Current Procedural Terminology (published by the American Medical Association) or Snomed (product of the College of American Pathologists), can introduce differences in disease codification. Finally, EMR is a physician dependent activity, Richard A. Young et al. published an observational study in which they found that PHC physicians spent more time in direct ambulatory patient care working in the EMR than they spent in face-to-face time with their patients, authors also recognized the existence of differences between time spending in EMR between American and European physicians ([@B35]).

The findings of our intervention support previous reports that effective ASPs not only improve antibiotic use but can also be financially self-supporting ([@B3]). In 2015 Dimitri M. Drekonja et al. evaluated the costs of effect of outpatient ASPs through a systematic review. The authors found only seven out of 50 studies in which dispensing costs were reported, significant cost reductions associated to ASPs were found in three, the authors admitted that drug costs were not universally reported ([@B4]). Future outpatient ASPs should include economic analysis in order to confirm the generalizability of our results.

Our study has some limitations. First, our data did not include information on antibiotic prescriptions issued in private practice; second, we were unable to identify which components of the ASP were the most effective; third, we did not have data on antibiotic therapy duration; fourth, as we did not cover a complete geographical region, we were unable to measure the impact of the intervention on the prevalence of antimicrobial resistance; and fifth, we did not have a comparison group.

We decided to perform a quasi-experimental study to avoid the risk of cross-contamination described in other behavioral intervention studies. In 2016, Stewardson et al. published a single center, cluster randomized trial to assess the effect of enhanced performance feedback and patient participation on hand hygiene. The improvement attributable to patient participation did not reach statistical significance and the authors recognized the existence of an unavoidable cross-contamination effect ([@B25]). As our PHC area forms part of a centralized health care structure in which all professionals receive the same training and have access to the same information, it would have been impossible to avoid cross-contamination.

Our findings add to the body of evidence on the effectiveness of ASPs in several respects. We have provided qualitative, quantitative, and economic indicators on the effectiveness of a multifaceted intervention targeting both adult and pediatric patients and ours is one of few studies in Spain to analyze the impact in nursing homes. Finally, we analyzed the sustainability of our program by measuring post-intervention effects.

Conclusions {#s5}
===========

Through a multimodal intervention, we were able to reduce antibiotic consumption, increase the use of narrow-spectrum antibiotics, and significantly improve the use of antibiotics to treat the most prevalent infections seen in PHC. Further studies should examine the generalizability of these findings to other health care systems.
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